685 related articles for article (PubMed ID: 27639803)
21. Genomic sequencing identifies a few mutations driving the independent origin of primary liver tumors in a chronic hepatitis murine model.
Yang Z; Jia M; Liu G; Hao H; Chen L; Li G; Liu S; Li Y; Wu CI; Lu X; Wang S
PLoS One; 2017; 12(11):e0187551. PubMed ID: 29117265
[TBL] [Abstract][Full Text] [Related]
22. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
24. A Pharmacogenomic Landscape in Human Liver Cancers.
Qiu Z; Li H; Zhang Z; Zhu Z; He S; Wang X; Wang P; Qin J; Zhuang L; Wang W; Xie F; Gu Y; Zou K; Li C; Li C; Wang C; Cen J; Chen X; Shu Y; Zhang Z; Sun L; Min L; Fu Y; Huang X; Lv H; Zhou H; Ji Y; Zhang Z; Meng Z; Shi X; Zhang H; Li Y; Hui L
Cancer Cell; 2019 Aug; 36(2):179-193.e11. PubMed ID: 31378681
[TBL] [Abstract][Full Text] [Related]
25. Multi-regional sequencing reveals intratumor heterogeneity and positive selection of somatic mtDNA mutations in hepatocellular carcinoma and colorectal cancer.
Li X; Guo X; Li D; Du X; Yin C; Chen C; Fang W; Bian Z; Zhang J; Li B; Yang H; Xing J
Int J Cancer; 2018 Sep; 143(5):1143-1152. PubMed ID: 29569724
[TBL] [Abstract][Full Text] [Related]
26. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
27. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Gerlinger M; Rowan AJ; Horswell S; Math M; Larkin J; Endesfelder D; Gronroos E; Martinez P; Matthews N; Stewart A; Tarpey P; Varela I; Phillimore B; Begum S; McDonald NQ; Butler A; Jones D; Raine K; Latimer C; Santos CR; Nohadani M; Eklund AC; Spencer-Dene B; Clark G; Pickering L; Stamp G; Gore M; Szallasi Z; Downward J; Futreal PA; Swanton C
N Engl J Med; 2012 Mar; 366(10):883-892. PubMed ID: 22397650
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
29. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2020 May; ():. PubMed ID: 32428506
[TBL] [Abstract][Full Text] [Related]
30. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
[TBL] [Abstract][Full Text] [Related]
31. Identification of trunk mutations in gastric carcinoma: a case study.
Zhou Z; Wu S; Lai J; Shi Y; Qiu C; Chen Z; Wang Y; Gu X; Zhou J; Chen S
BMC Med Genomics; 2017 Jul; 10(1):49. PubMed ID: 28716121
[TBL] [Abstract][Full Text] [Related]
32. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
[TBL] [Abstract][Full Text] [Related]
33. Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.
Mota A; Oltra SS; Selenica P; Moiola CP; Casas-Arozamena C; López-Gil C; Diaz E; Gatius S; Ruiz-Miro M; Calvo A; Rojo-Sebastián A; Hurtado P; Piñeiro R; Colas E; Gil-Moreno A; Reis-Filho JS; Muinelo-Romay L; Abal M; Matias-Guiu X; Weigelt B; Moreno-Bueno G
Oncogene; 2022 Mar; 41(13):1835-1850. PubMed ID: 35145232
[TBL] [Abstract][Full Text] [Related]
34. Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma.
Woo HG; Kim SS; Cho H; Kwon SM; Cho HJ; Ahn SJ; Park ES; Lee JS; Cho SW; Cheong JY
PLoS One; 2014; 9(12):e115152. PubMed ID: 25521761
[TBL] [Abstract][Full Text] [Related]
35. Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma.
Lin DC; Mayakonda A; Dinh HQ; Huang P; Lin L; Liu X; Ding LW; Wang J; Berman BP; Song EW; Yin D; Koeffler HP
Cancer Res; 2017 May; 77(9):2255-2265. PubMed ID: 28302680
[TBL] [Abstract][Full Text] [Related]
36. In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment.
Hirschfield H; Bian CB; Higashi T; Nakagawa S; Zeleke TZ; Nair VD; Fuchs BC; Hoshida Y
Exp Mol Med; 2018 Jan; 50(1):e419. PubMed ID: 29303513
[TBL] [Abstract][Full Text] [Related]
37. Intratumor heterogeneity in hepatocellular carcinoma.
Friemel J; Rechsteiner M; Frick L; Böhm F; Struckmann K; Egger M; Moch H; Heikenwalder M; Weber A
Clin Cancer Res; 2015 Apr; 21(8):1951-61. PubMed ID: 25248380
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
39. Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer.
Hlady RA; Zhou D; Puszyk W; Roberts LR; Liu C; Robertson KD
Epigenetics; 2017 Mar; 12(3):215-225. PubMed ID: 28059585
[TBL] [Abstract][Full Text] [Related]
40. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
